Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
ARQT 10.23.2024
About Gravity Analytica
Recent News
- 02.25.2025 - Arcutis Biotherapeutics, Inc. Q4 2024 Earnings Conference Call
- 01.12.2025 - Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
- 01.06.2025 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Recent Filings
- Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ET
- Arcutis management will also participate in the Guggenheim Securities Healthcare Innovation Conference in November
WESTLAKE VILLAGE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) --Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report third quarter 2024 financial results and provide a business update on Wednesday, November 6, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and the presentation materials will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available in the same location following the conference call.
Arcutis also announced its participation for an upcoming investor conference. Details for the company’s participation are as follows:
- Guggenheim’s Inaugural Healthcare Innovation ConferenceFireside Chat Date/Time:Monday, November 11 at 3:30 p.m. ET
A live webcast for this event may be accessed at the “Events” section of the Company’s website. An archived replay of the fireside chat will be available in the same location following the event.
About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visitwww.arcutis.comor follow Arcutis onLinkedIn,Facebook,Instagram, andX.
Forward-Looking StatementsArcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, and the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
MediaAmanda Sheldon, Head of Corporate Communicationsmedia@arcutis.com
InvestorsLatha Vairavan, Vice President, Finance and Corporate Controllerir@arcutis.com
